MARKET

AEMD

AEMD

Aethlon Medical
NASDAQ
2.166
+0.016
+0.73%
Opening 11:39 03/30 EDT
OPEN
2.150
PREV CLOSE
2.150
HIGH
2.210
LOW
2.050
VOLUME
6.70K
TURNOVER
--
52 WEEK HIGH
35.20
52 WEEK LOW
1.360
MARKET CAP
3.40M
P/E (TTM)
-0.0441
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AEMD last week (0323-0327)?
Weekly Report · 13h ago
Aethlon Medical publishes Hemopurifier platform presentation; cash totals $7.0 million at Dec. 31, 2025
Reuters · 3d ago
Aethlon Medical Announces Independent Data Safety Monitoring Board Completes Its Safety Review For AEMD-2022-06; Finds No Safety Concerns; Recommends Third And Final Cohort
Benzinga · 6d ago
Aethlon Medical advances to final cohort in AEMD-2022-06 trial
TipRanks · 6d ago
Aethlon Medical opens final cohort in Hemopurifier oncology trial after DSMB review finds no safety concerns
Reuters · 6d ago
AETHLON MEDICAL INC: DSMB ALSO STATED THAT "NO SAFETY CONCERNS WERE NOTED WITH HEMOPURIFIER DEVICE/PROCEDURE"
Reuters · 6d ago
Weekly Report: what happened at AEMD last week (0316-0320)?
Weekly Report · 03/23 10:27
Aethlon Medical Completes Pre-Funded Warrant Exercises, Simplifying Equity
TipRanks · 03/17 13:52
More
About AEMD
Aethlon Medical, Inc. is a clinical-stage medical device company. The Company is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.

Webull offers Aethlon Medical Inc stock information, including NASDAQ: AEMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AEMD stock methods without spending real money on the virtual paper trading platform.